Multiple facets of NF-κB in the heart: to be or not to NF-κB

Joseph W Gordon1, James A Shaw, Lorrie A Kirshenbaum

  • 1Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada.

Circulation Research
|April 30, 2011
PubMed

Insights

Nuclear factor kappa B (NF-κB) plays a dual role in heart failure, offering protection in acute injury but causing damage with prolonged activation. Understanding NF-κB

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cellular Signaling

Background:

  • Heart failure progression involves cardiac myocyte loss via necrosis, apoptosis, and autophagy.
  • Investigating molecular regulators of cell death pathways is crucial for therapeutic targets.
  • Nuclear factor kappa B (NF-κB) is a transcription factor family involved in cell survival and inflammation.

Purpose of the Study:

  • To elucidate the mechanisms behind the differential effects of NF-κB on cardiac cell fate.
  • To propose a novel paradigm explaining NF-κB's context-dependent roles in myocardial injury.
  • To identify potential therapeutic strategies targeting NF-κB signaling in heart failure.

Main Methods:

  • Review and synthesis of existing literature on NF-κB signaling in cardiac myocytes.
  • Analysis of studies investigating NF-κB's role in acute versus chronic cardiac conditions.
  • Hypothesizing a mechanistic model based on timing, duration, and cellular context of NF-κB activation.

Main Results:

  • NF-κB demonstrates cardioprotective effects during acute hypoxia and reperfusion injury.
  • Prolonged NF-κB activation promotes heart failure through chronic inflammation and endoplasmic reticulum stress.
  • Differential outcomes of NF-κB signaling are linked to its activation kinetics and cellular environment.

Conclusions:

  • The timing, duration, and cellular context of NF-κB activation critically determine its impact on cardiac cell fate.
  • A nuanced understanding of NF-κB signaling is essential for developing targeted heart failure therapies.
  • Future interventions may involve modulating NF-κB responses to mitigate myocardial injury and prevent heart failure progression.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...